German team advises Velocity Clinical Research on the acquisition of two clinical research sites in Germany

Global Press release - Business February 2024

Global law firm Norton Rose Fulbright has advised Velocity Clinical Research (Velocity), a portfolio company of GHO Capital (Global Healthcare Opportunities), Europe's leading private equity investor in the healthcare sector, on the acquisition of Pneumological Research Institute at LungenClinic Grosshansdorf (PRI) and KLB Gesundheitsforschung Lübeck (KLB).

Headquartered in the United States, Velocity is the world's leading integrated multi-specialty site organisation for clinical trials and, following, inter alia, the acquisitions of PRI and KLB, now one of the largest site organisations in Europe. In addition to it being the largest sites business in the United States with more than 75 trial sites and more than 220 principal investigators, Velocity now has a network of 17 sites across three countries in Europe. Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and well-being. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staffs for Phase 1-4 clinical trials across the United States and Europe. Velocity's integrated approach benefits Sponsors, Contract Research Organisations ("CRO") and study participants.

PRI is a leader in research into bronchial asthma, bronchiectasis and pulmonary fibrosis and has conducted over 300 studies since it opened 25 years ago. KLB has also conducted clinical studies for respiratory diseases since 2008 and is dedicated to researching new active principles and diagnostic procedures in the treatment of chronic obstructive respiratory diseases such as bronchial asthma and COPD.

Norton Rose Fulbright advised Velocity with a team led by Johannes Diez and Dr Nicolas Daamen (both Corporate / M&A, Munich). Including the acquisitions of PRI and KLB, Diez and Daamen have now advised Velocity on six transactions in Germany, including Velocity's first investment in Europe (acquisition of Hamburg-based Clinical Research Hamburg in July 2022) and most recently on the acquisition of Klinische Forschung Berlin in August 2023.

In addition to Diez and Daamen, the Norton Rose Fulbright team that advised Velocity on the transactions comprised Dr Maren Stölting, Dr Britta Jilge (both Real Estate, Munich), Claudia Posluschny, Christina Wiesel (both Employment, Munich) and Tobias Grans (Corporate / M&A, Munich).

For further information please contact:

Julian Krauskopf, Corporate Communications & PR Executive

Tel: +49 211 97559 755  


Senior Associate